Hodgkin lymphoma (HL) is a lymphoproliferative malignancy of B-cell origin that accounts for 10% of all lymphomas. Despite evidence suggesting strong familial clustering of HL, there is no clear understanding of the contribution of genes predisposing to HL. In this study, whole genome sequencing (WGS) was performed on 7 affected and 9 unaffected family members from three HL-prone families and variants were prioritized using our Familial Cancer Variant Prioritization Pipeline (FCVPPv2). WGS identified a total of 98,564, 170,550, and 113,654 variants which were reduced by pedigree-based filtering to 18,158, 465, and 26,465 in families I, II, and III, respectively. In addition to variants affecting amino acid sequences, variants in promoters, enhancers, transcription factors binding sites, and microRNA seed sequences were identified from upstream, downstream, 5' and 3' untranslated regions. A panel of 565 cancer predisposing and other cancer-related genes and of 2,383 potential candidate HL genes were also screened in these families to aid further prioritization. Pathway analysis of segregating genes with Combined Annotation Dependent Depletion Tool (CADD) scores >20 was performed using Ingenuity Pathway Analysis software which implicated several candidate genes in pathways involved in B-cell activation and proliferation and in the network of "Cancer, Hematological disease and Immunological Disease." We used the FCVPPv2 for further in silico analyses and prioritized 45 coding and 79 non-coding variants from the three families. Further literature-based analysis allowed us to constrict this list to one rare germline variant each in families I and II and two in family III. Functional studies were conducted on the candidate from family I in a previous study, resulting in the identification and functional validation of a novel heterozygous missense variant in the tumor suppressor gene DICER1 as potential HL predisposition factor. We aim to identify the individual genes responsible for predisposition in the remaining two families and will functionally validate these in further studies.

Computational Oncology Molecular Diagnostics Program National Center for Tumor Diseases Heidelberg Germany

Department of Genetics and Pathology International Hereditary Cancer Centre Pomeranian Medical University Szczecin Poland

Department of Pediatric Oncology Hematology and Immunology University of Heidelberg Heidelberg Germany

Division of Molecular Genetic Epidemiology German Cancer Research Center Heidelberg Germany

Division of Pediatric Neurooncology German Cancer Research Center Heidelberg Germany

Faculty of Medicine and Biomedical Center in Pilsen Charles University Prague Pilsen Czechia

Hopp Children's Cancer Center Heidelberg Germany

Medical Faculty Heidelberg University Heidelberg Germany

Zobrazit více v PubMed

Ackermann A., Brieger A. (2019). The role of nonerythroid spectrin αII in cancer. J. Oncol. 2019:7079604. 10.1155/2019/7079604 PubMed DOI PMC

Agarwal V., Bell G. W., Nam J. W., Bartel D. P. (2015). Predicting effective microRNA target sites in mammalian mRNAs. Elife 4, 1–14. 10.7554/eLife.05005.028 PubMed DOI PMC

Bandapalli O. R., Paramasivam N., Giangiobbe S., Kumar A., Benisch W., Engert A., et al. . (2018). Whole genome sequencing reveals DICER1 as a candidate predisposing gene in familial Hodgkin lymphoma. Int J Cancer 143, 2076–2078. 10.1002/ijc.31576 PubMed DOI

Banerjee S., Kaye S. B., Ashworth A. (2010). Making the best of PARP inhibitors in ovarian cancer. Nat. Rev. Clin. Oncol. 7, 508–519. 10.1038/nrclinonc.2010.116 PubMed DOI

Betel D., Koppal A., Agius P., Sander C., Leslie C. (2010). Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol. 11:R90. 10.1186/gb-2010-11-8-r90 PubMed DOI PMC

Birney E., Stamatoyannopoulos J. A., Dutta A., Guigó R., Gingeras T. R., Margulies E. H., et al. . (2007). Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447, 799–816. 10.1038/nature05874 PubMed DOI PMC

Boyle A. P., Hong E. L., Hariharan M., Cheng Y., Schaub M. A., Kasowski M., et al. . (2012). Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 22, 1790–1797. 10.1101/gr.137323.112 PubMed DOI PMC

Buggy J. J., Elias L. (2012). Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int. Rev. Immunol. 31, 119–132. 10.3109/08830185.2012.664797 PubMed DOI

Chen X., Li Y., Ouyang T., Li J., Wang T., Fan Z., et al. . (2018). Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers. Ann. Oncol. 29, 2046–2051. 10.1093/annonc/mdy338 PubMed DOI

Cooper G. M., Stone E. A., Asimenos G., Program N. C. S., Green E. D., Batzoglou S., et al. . (2005). Distribution and intensity of constraint in mammalian genomic sequence. Genome Res. 15, 901–913. 10.1101/gr.3577405 PubMed DOI PMC

Cozen W., Timofeeva M. N., Li D., Diepstra A., Hazelett D., Delahaye-Sourdeix M., et al. . (2014). A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus. Nat. Commun. 5:3856. 10.1038/ncomms4856 PubMed DOI PMC

Cybulski C., Wokolorczyk D., Huzarski T., Byrski T., Gronwald J., Gorski B., et al. . (2006). A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. J. Med. Genet. 43, 863–866. 10.1136/jmg.2006.044974 PubMed DOI PMC

Dayem Ullah A. Z., Oscanoa J., Wang J., Nagano A., Lemoine N. R., Chelala C. (2018). SNPnexus: assessing the functional relevance of genetic variation to facilitate the promise of precision medicine. Nucleic Acids Res. 46, W109–W113. 10.1093/nar/gky399 PubMed DOI PMC

Diehl V., Thomas R. K., Re D. (2004). Part II: Hodgkin's lymphoma–diagnosis and treatment. Lancet Oncol. 5, 19–26. 10.1016/S1470-2045(03)01320-2 PubMed DOI

Diepstra A., Niens M., Vellenga E., Van Imhoff G. W., Nolte I. M., Schaapveld M., et al. . (2005). Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma. Lancet 365, 2216–2224. 10.1016/S0140-6736(05)66780-3 PubMed DOI

Dreyling M., Santoro A., Mollica L., Leppa S., Follows G. A., Lenz G., et al. . (2017). Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J. Clin. Oncol. 35, 3898–3905. 10.1200/JCO.2017.75.4648 PubMed DOI

Frampton M., Da Silva Filho M. I., Broderick P., Thomsen H., Forsti A., Vijayakrishnan J., et al. . (2013). Variation at 3p24.1 and 6q23.3 influences the risk of Hodgkin's lymphoma. Nat. Commun. 4:2549. 10.1038/ncomms3549 PubMed DOI PMC

Ge J., Yu Y., Xin F., Yang Z. J., Zhao H. M., Wang X., et al. . (2017). Downregulation of delta-aminolevulinate dehydratase is associated with poor prognosis in patients with breast cancer. Cancer Sci. 108, 604–611. 10.1111/cas.13180 PubMed DOI PMC

Kharazmi E., Fallah M., Pukkala E., Olsen J. H., Tryggvadottir L., Sundquist K., et al. . (2015). Risk of familial classical Hodgkin lymphoma by relationship, histology, age, and sex: a joint study from five Nordic countries. Blood 126, 1990–1995. 10.1182/blood-2015-04-639781 PubMed DOI

Kircher M., Witten D. M., Jain P., O'roak B. J., Cooper G. M., Shendure J. (2014). A general framework for estimating the relative pathogenicity of human genetic variants. Nat. Genet. 46, 310–315. 10.1038/ng.2892 PubMed DOI PMC

Kopanos C., Tsiolkas V., Kouris A., Chapple C. E., Albarca Aguilera M., Meyer R., et al. . (2018). VarSome: the human genomic variant search engine. Bioinformatics 35, 1978–1980. 10.1093/bioinformatics/bty897 PubMed DOI PMC

Kumar A., Bandapalli O. R., Paramasivam N., Giangiobbe S., Diquigiovanni C., Bonora E., et al. . (2018). Familial cancer variant prioritization pipeline version 2 (FCVPPv2) applied to a papillary thyroid cancer family. Sci. Rep. 8:11635. 10.1038/s41598-018-29952-z PubMed DOI PMC

Kuppers R. (2009). The biology of Hodgkin's lymphoma. Nat. Rev. Cancer 9, 15–27. 10.1038/nrc2542 PubMed DOI

Kushekhar K., Van Den Berg A., Nolte I., Hepkema B., Visser L., Diepstra A. (2014). Genetic associations in classical hodgkin lymphoma: a systematic review and insights into susceptibility mechanisms. Cancer Epidemiol. Biomarkers Prev. 23:2737–2747. 10.1158/1055-9965.EPI-14-0683 PubMed DOI

Lek M., Karczewski K. J., Minikel E. V., Samocha K. E., Banks E., Fennell T., et al. . (2016). Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291. 10.1038/nature19057 PubMed DOI PMC

Li H. (2011). A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. Bioinformatics 27, 2987–2993. 10.1093/bioinformatics/btr509 PubMed DOI PMC

Li H., Durbin R. (2009). Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760. 10.1093/bioinformatics/btp324 PubMed DOI PMC

Liu D., Mamorska-Dyga A. (2017). Syk inhibitors in clinical development for hematological malignancies. J. Hematol. Oncol. 10:145. 10.1186/s13045-017-0512-1 PubMed DOI PMC

Liu X., Wu C., Li C., Boerwinkle E. (2016). dbNSFP v3.0: a one-stop database of functional predictions and annotations for human nonsynonymous and splice-site SNVs. Hum. Mutat. 37, 235–241. 10.1002/humu.22932 PubMed DOI PMC

Loveday C., Turnbull C., Ramsay E., Hughes D., Ruark E., Frankum J. R., et al. . (2011). Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat. Genet. 43, 879–882. 10.1038/ng.893 PubMed DOI PMC

Ma L. J., Wu W. J., Wang Y. H., Wu T. F., Liang P. I., Chang I. W., et al. . (2016). SPOCK1 overexpression confers a poor prognosis in urothelial carcinoma. J. Cancer 7, 467–476. 10.7150/jca.13625 PubMed DOI PMC

Mcmaster M. L., Sun C., Landi M. T., Savage S. A., Rotunno M., Yang X. R., et al. . (2018). Germline mutations in protection of telomeres 1 in two families with Hodgkin lymphoma. Br. J. Haematol. 181, 372–377. 10.1111/bjh.15203 PubMed DOI PMC

Ngan E., Kiepas A., Brown C. M., Siegel P. M. (2018). Emerging roles for LPP in metastatic cancer progression. J. Cell Commun. Signal. 12, 143–156. 10.1007/s12079-017-0415-5 PubMed DOI PMC

Palles C., Cazier J. B., Howarth K. M., Domingo E., Jones A. M., Broderick P., et al. . (2013). Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat. Genet. 45, 136–144. 10.1038/ng.2503 PubMed DOI PMC

Petrovski S., Wang Q., Heinzen E. L., Allen A. S., Goldstein D. B. (2013). Genic intolerance to functional variation and the interpretation of personal genomes. PLoS Genet. 9:e1003709. 10.1371/annotation/32c8d343-9e1d-46c6-bfd4-b0cd3fb7a97e PubMed DOI PMC

Pollard K. S., Hubisz M. J., Rosenbloom K. R., Siepel A. (2010). Detection of nonneutral substitution rates on mammalian phylogenies. Genome Res. 20, 110–121. 10.1101/gr.097857.109 PubMed DOI PMC

Rimmer A., Phan H., Mathieson I., Iqbal Z., Twigg S. R. F., Consortium W. G. S., et al. . (2014). Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications. Nat. Genet. 46, 912–918. 10.1038/ng.3036 PubMed DOI PMC

Ristolainen H., Kilpivaara O., Kamper P., Taskinen M., Saarinen S., Leppa S., et al. . (2015). Identification of homozygous deletion in ACAN and other candidate variants in familial classical Hodgkin lymphoma by exome sequencing. Br. J. Haematol. 170, 428–431. 10.1111/bjh.13295 PubMed DOI

Rotunno M., Mcmaster M. L., Boland J., Bass S., Zhang X., Burdett L., et al. . (2016). Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene. Haematologica 101, 853–860. 10.3324/haematol.2015.135475 PubMed DOI PMC

Saarinen S., Aavikko M., Aittomaki K., Launonen V., Lehtonen R., Franssila K., et al. . (2011). Exome sequencing reveals germline NPAT mutation as a candidate risk factor for Hodgkin lymphoma. Blood 118, 493–498. 10.1182/blood-2011-03-341560 PubMed DOI

Salipante S. J., Mealiffe M. E., Wechsler J., Krem M. M., Liu Y., Namkoong S., et al. . (2009). Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cells. Proc. Natl. Acad. Sci. U.S.A. 106, 14920–14925. 10.1073/pnas.0904231106 PubMed DOI PMC

Siepel A., Bejerano G., Pedersen J. S., Hinrichs A. S., Hou M., Rosenbloom K., et al. . (2005). Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res. 15, 1034–1050. 10.1101/gr.3715005 PubMed DOI PMC

Smigielski E. M., Sirotkin K., Ward M., Sherry S. T. (2000). dbSNP: a database of single nucleotide polymorphisms. Nucleic Acids Res. 28, 352–355. 10.1093/nar/28.1.352 PubMed DOI PMC

Srivastava A., Kumar A., Giangiobbe S., Bonora E., Hemminki K., Forsti A., et al. . (2019). Whole genome sequencing of familial non-medullary thyroid cancer identifies germline alterations in MAPK/ERK and PI3K/AKT signaling pathways. Biomolecules 9:E605. 10.3390/biom9100605 PubMed DOI PMC

Tan D. E. K., Foo J. N., Bei J.-X., Chang J., Peng R., Zheng X., et al. . (2013). Genome-wide association study of B cell non-Hodgkin lymphoma identifies 3q27 as a susceptibility locus in the Chinese population. Nat. Genet. 45:804. 10.1038/ng.2666 PubMed DOI

The Genomes Project Consortium. Auton A., Abecasis G. R., Altshuler D. M., Durbin R. M., Abecasis G. R., et al. . (2015). A global reference for human genetic variation. Nature 526, 68–74. 10.1038/nature15393 PubMed DOI PMC

Valla K., Flowers C. R., Koff J. L. (2018). Targeting the B cell receptor pathway in non-Hodgkin lymphoma. Expert Opin. Investig. Drugs 27, 513–522. 10.1080/13543784.2018.1482273 PubMed DOI PMC

Wang K., Li M., Hakonarson H. (2010). ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38:e164. 10.1093/nar/gkq603 PubMed DOI PMC

Ward L. D., Kellis M. (2012). HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 40, D930–D934. 10.1093/nar/gkr917 PubMed DOI PMC

Wong K., Robles-Espinoza C. D., Rodriguez D., Rudat S. S., Puig S., Potrony M., et al. . (2019). Association of the POT1 germline missense variant p.I78T with familial melanoma. JAMA Dermatol. 155, 604–609. 10.1001/jamadermatol.2018.3662 PubMed DOI PMC

Zhang J., Walsh M. F., Wu G., Edmonson M. N., Gruber T. A., Easton J., et al. . (2015). Germline mutations in predisposition genes in pediatric cancer. N. Engl. J. Med. 373, 2336–2346. 10.1056/NEJMoa1508054 PubMed DOI PMC

Whole exome sequencing identifies novel germline variants of SLC15A4 gene as potentially cancer predisposing in familial colorectal cancer

Germline Variants of CYBA and TRPM4 Predispose to Familial Colorectal Cancer

Whole Exome Sequencing Identifies APCDD1 and HDAC5 Genes as Potentially Cancer Predisposing in Familial Colorectal Cancer